Literature DB >> 10981163

Aldosterone-related genetic effects in hypertension.

D G Warnock1.   

Abstract

Our basic understanding of Na(+) transport mechanisms provides unique insights into epithelial transport processes. Unusual clinical syndromes can arise from mutations of these ion transporters. These genetic disorders affect Na(+) balance, resulting in both N(a+) retaining and Na(+) wasting conditions. A major focus has been the epithelial sodium channel (ENaC), which can be activated by mutations (eg, Liddle's syndrome), changes in the response to mineralocorticoids (apparent mineralocorticoid excess syndrome), or production of mineralocorticoids (glucocorticoid-remediable aldosteronism). As a result, we now have clearly defined Mendelian syndromes in which ENaC activity is "dysregulated." This dysregulation leads to systemic hypertension associated with suppressed plasma renin activity, which can be attributed to a primary renal mechanism. Applying these insights to the far more common disorder of low-renin hypertension may shed new light on the underlying pathophysiology of this common form of human hypertension.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10981163     DOI: 10.1007/s11906-000-0013-3

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  48 in total

1.  Loss of protein kinase C inhibition in the beta-T594M variant of the amiloride-sensitive Na+ channel.

Authors:  Y Cui; Y R Su; M Rutkowski; M Reif; A G Menon; R Y Pun
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

2.  A new polymorphic restriction site in the human 11 beta-hydroxysteroid dehydrogenase type 2 gene.

Authors:  Z Smolenicka; E Bach; A Schaer; S Liechti-Gallati; B M Frey; F J Frey; P Ferrari
Journal:  J Clin Endocrinol Metab       Date:  1998-05       Impact factor: 5.958

Review 3.  Polymorphism in the beta subunit and Na+ transport.

Authors:  D G Warnock
Journal:  J Am Soc Nephrol       Date:  1996-12       Impact factor: 10.121

4.  Alterations in aldosterone secretion and metabolism in low renin hypertension.

Authors:  G T Griffing; T E Wilson; J C Melby
Journal:  J Clin Endocrinol Metab       Date:  1990-12       Impact factor: 5.958

5.  Sodium status, corticosteroid metabolism and blood pressure in normal human subjects and in a patient with abnormal salt appetite.

Authors:  M C Ingram; A M Wallace; A Collier; R Fraser; J M Connell
Journal:  Clin Exp Pharmacol Physiol       Date:  1996-05       Impact factor: 2.557

6.  Genotype-phenotype analysis of a newly discovered family with Liddle's syndrome.

Authors:  X Jeunemaitre; F Bassilana; A Persu; C Dumont; G Champigny; M Lazdunski; P Corvol; P Barbry
Journal:  J Hypertens       Date:  1997-10       Impact factor: 4.844

7.  Mass spectrometry in the diagnosis of steroid-related disorders and in hypertension research.

Authors:  C H Shackleton
Journal:  J Steroid Biochem Mol Biol       Date:  1993-04       Impact factor: 4.292

8.  Deficient inactivation of cortisol by 11 beta-hydroxysteroid dehydrogenase in essential hypertension.

Authors:  B R Walker; P M Stewart; C H Shackleton; P L Padfield; C R Edwards
Journal:  Clin Endocrinol (Oxf)       Date:  1993-08       Impact factor: 3.478

9.  Liddle disease caused by a missense mutation of beta subunit of the epithelial sodium channel gene.

Authors:  H Tamura; L Schild; N Enomoto; N Matsui; F Marumo; B C Rossier
Journal:  J Clin Invest       Date:  1996-04-01       Impact factor: 14.808

10.  Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase.

Authors:  T Mune; F M Rogerson; H Nikkilä; A K Agarwal; P C White
Journal:  Nat Genet       Date:  1995-08       Impact factor: 38.330

View more
  6 in total

Review 1.  Pathophysiology and treatment of resistant hypertension: the role of aldosterone and amiloride-sensitive sodium channels.

Authors:  Eric K Judd; David A Calhoun; David G Warnock
Journal:  Semin Nephrol       Date:  2014       Impact factor: 5.299

2.  Aldosterone-sensitive repression of ENaCalpha transcription by a histone H3 lysine-79 methyltransferase.

Authors:  Wenzheng Zhang; Xuefeng Xia; Diana I Jalal; Teresa Kuncewicz; William Xu; Gene D Lesage; Bruce C Kone
Journal:  Am J Physiol Cell Physiol       Date:  2005-10-19       Impact factor: 4.249

3.  Management of Resistant Hypertension: Do Not Give Up on Medication.

Authors:  Eric Judd; David A Calhoun
Journal:  Nephrol Self Assess Program       Date:  2014-03

4.  New mechanisms for transcriptional repression of ENaC And iNOS.

Authors:  Bruce C Kone; Zhang Wenzhang; Yu Zhiyuan
Journal:  Trans Am Clin Climatol Assoc       Date:  2007

Review 5.  Direct activation of ENaC by angiotensin II: recent advances and new insights.

Authors:  Oleg Zaika; Mykola Mamenko; Alexander Staruschenko; Oleh Pochynyuk
Journal:  Curr Hypertens Rep       Date:  2013-02       Impact factor: 5.369

6.  Pediatric endocrine hypertension.

Authors:  Nisha Bhavani
Journal:  Indian J Endocrinol Metab       Date:  2011-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.